|View printer-friendly version|
|February 11, 2005 9:58 a.m.|
|Teva And Savient Launch Tev-Tropin™ For Pediatric Growth Hormone Deficiency|
Jerusalem, Israel, February 11, 2005 - Teva Pharmaceuticals Industries Ltd. (Nasdaq: TEVA) and Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) have announced the U.S. launch of TEV-TROPIN™ (somatropin [rDNA origin] for injection), a growth hormone product for the treatment of children with short stature due to growth hormone deficiency. This product was clinically tested and FDA-approved for growth hormone deficiency (GHD), and is manufactured by Savient using recombinant DNA (rDNA) technology.